Assessing the Safety and Efficacy of a Novel Subcutaneous Implant Insertion Device on Healthy Adults
Assessing the Safety and Efficacy of the SubQ Assist Implant Insertion Device
The investigators have created a device designed to make it easier to insert pharmaceutical implants under the skin. The device uses a blood pressure cuff to hold the skin on a person's arm in place while a mechanical guide places implants underneath the skin. This device may prevent implants from being embedded too deeply.
The investigators are performing this study to determine the safety and efficacy of the device for use in adult women. The study will determine if the implants are placed accurately under the skin (in the sub-dermal layer). It will also assess if the device causes any discomfort or last pain from use.
Tutkimuksen yleiskatsaus
Yksityiskohtainen kuvaus
Subcutaneous contraceptive implants are one of the preferred methods of long-term contraception by the World health Organization and ministries of health in low- and middle-income countries. These implants offer between three and five years of protection (allowing women to safely space pregnancies and thereby reduce maternal and infant mortality), are 99.95% efficacious, allow women to return to fertility quickly when removed, requires no daily/monthly effort on the part of the woman, and cause minimal side effects in comparison to other methods. However, availability of contraceptive implants in rural areas is limited due to the skill necessary to administer them safely and accurately.
The investigators have created a device designed to make it easier to insert pharmaceutical implants under the skin. The device uses a blood pressure cuff to hold the skin on a person's arm in place while a mechanical guide places implants underneath the skin. This device is designed to prevent implants from being embedded too deeply.
In this trial, the investigators will use the implant insertion device with a placebo sub-cutaneous implant. Implants will be inserted with the device and the accuracy of the placement will be assessed through palpation and ultrasound depth measurements. This data will allow the investigators to assess whether the device ensures accurate insertions of sub-cutaneous implants.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Michigan
-
Ann Arbor, Michigan, Yhdysvallat, 48109
- University of Michigan
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Healthy adult subjects aged 18 to 49
- Ability to understand study procedure and informed consent document
Exclusion Criteria:
- Patients with a history of keloid scarring
- Pregnancy
- Any rashes or skin conditions around the insertion site
- Known silicone allergies
- Known allergy to lidocaine
- History of bleeding disorders or abnormal bleeding
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Perustiede
- Jako: Ei käytössä
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Single arm study: implant insertion
Participants in trial will be within a single study arm.
All participants will have a placebo subcutaneous implant inserted with the device being studied.
The implant accuracy will be assess through palpation and ultrasound depth measurements.
The implant will then be removed.
Safety will be assessed by measuring bruising and bleeding.
A follow-up questionnaire will assess bruising and infection risk.
A final visit will assess bruising and infection risk by a physician.
|
Device designed to assist healthcare providers in administering subcutaneous implants safely and accurately.
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Implant Depth: Distal End
Aikaikkuna: Up to 60 minutes after insertion
|
Depth of distal end of implant beneath the skin after insertion.
Measured via high frequency ultrasound with linear probe.
Measured in centimeters below skin surface.
Measurements will be aggregated via mean and standard deviation.
|
Up to 60 minutes after insertion
|
|
Implant Depth: Proximal End
Aikaikkuna: Up to 60 minutes after insertion
|
Depth of distal end of implant beneath the skin after insertion.
Measured via high frequency ultrasound with linear probe.
Measured in centimeters below skin surface.
Measurements will be aggregated via mean and standard deviation.
|
Up to 60 minutes after insertion
|
|
Implant Palpability
Aikaikkuna: Up to 15 minutes after insertion
|
A binary (yes/no) assessment of whether the implant is palpable by a physician under the skin after insertion.
Measurements will be aggregated based on percent of implants that are palpable.
|
Up to 15 minutes after insertion
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Number of Participants With Bruising
Aikaikkuna: Up to 15 minutes after insertion.
|
Bruising may occur from inflation of the blood pressure cuff over the device being studied.
A binary assessment of bruising (yes/no) will be assessed by the physician after insertion.
|
Up to 15 minutes after insertion.
|
|
Presence of Bruising
Aikaikkuna: 7 to 14 days after insertion
|
Bruising may occur from inflation of the blood pressure cuff over the device being studied.
Bruising will be assessed by the participant in a survey (binary yes/no indication of bruising around insertion site).
|
7 to 14 days after insertion
|
|
Number of Participants With More Bleeding Than Typical
Aikaikkuna: Up to 10 minutes after insertion
|
Bleeding from insertion will be assessed by the physician who has extensive training with implant insertions.
The number of participants with more bleeding than is typically associated with insertion will be measured.
|
Up to 10 minutes after insertion
|
|
Number of Participants With Signs of Infection
Aikaikkuna: 7 to 10 days after insertion
|
Infection will be assessed during the follow-up questionnaire. A binary assessment (yes/no) of the following will be assessed by the participant. 1) Is there currently any fluid draining from the incision? 2) Is there currently any redness or swelling of the insertion site? 3) Is there currently any bleeding from the insertion site? Participants who answer "Yes" to all three questions are deemed to have shown signs of infection. |
7 to 10 days after insertion
|
|
Number of Participants With Signs of Infection
Aikaikkuna: 21 to 28 days after insertion
|
A follow-up appointment with all participants was conducted by the physician who administered the implant. A binary assessment (yes/no) of the following will be assessed for each participant by the physician. 1) Is there currently any fluid draining from the incision? 2) Is there currently any redness or swelling of the insertion site? 3) Is there currently any bleeding from the insertion site? If the physician answers "Yes" to all three questions, the participant is deemed to have shown signs of infection. |
21 to 28 days after insertion
|
Yhteistyökumppanit ja tutkijat
Sponsori
Yhteistyökumppanit
Tutkijat
- Päätutkija: Kathleen H Sienko, PhD, Associate professor
- Päätutkija: Carrie L Bell, MD, Assistant Professor
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muut tutkimustunnusnumerot
- SubQAssist0001
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Yhdysvalloissa valmistettu ja sieltä viety tuote
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .